The below represents select transactions

Sitka

Announced: 11/14/2023 | Value: Undisclosed

MTS served as exclusive financial advisor to Sitka on its merger with AristaMD

Redx Pharma

Announced: 10/18/2023 | Value: $17 million

MTS served as exclusive placement agent to Redx Pharma on its PIPE offering, which was priced at-the-money and with no warrant coverage

Zynerba Pharmaceuticals, Inc.

Announced: 08/14/2023 | Value: $60 million (plus up to $140 million in additional payments)

MTS served as exclusive financial advisor to Zynerba Pharmaceuticals, Inc. in its sale to Harmony Biosciences Holdings, Inc.

EQRx, Inc.

Announced: 08/01/2023 | Value: $1.1 billion

MTS served as financial advisor to EQRx, Inc. in its sale to Revolution Medicines

Quince Therapeutics

Announced: 7/24/2023 | Value: Up to $509 million

MTS served as exclusive financial advisor to Quince Therapeutics on its acquisition of EryDel

Limbix

Announced: 07/14/2023 | Value: Undisclosed

MTS served as exclusive financial advisor to Limbix in its sale to Big Health

Hisamitsu Pharmaceutical Co., Inc.

Announced: 07/13/2023 | Value: Undisclosed

MTS served as exclusive financial advisor to Hisamitsu Pharmaceutical in its acquisition of S-Cup and Lacalut brand from SSP Co., Ltd, a Sanofi Company

The Pill Club

Announced: 06/12/2023 | Value: Undisclosed

MTS served as exclusive financial advisor to The Pill Club in its sale of assets to Thirty Madison and Twentyeight Health

Chinook Therapeutics, Inc.

Announced: 06/12/2023 | Value: $3.2 billion

MTS served as financial advisor to Chinook Therapeutics on its sale to Novartis AG

Pear Therapeutics

Announced: 05/18/2023 | Value: Undisclosed

MTS served as exclusive financial advisor to Pear Therapeutics in its sale of assets to Click Therapeutics, Harvest Bio, Nox Health (Vestar), and Welt Corp.

CTI BioPharma

Announced: 05/10/2023 | Value: $1.7 billion

MTS served as financial advisor to CTI BioPharma on its sale to Swedish Orphan Biovitrum (SOBI)

Fujifilm

Announced: 05/10/2023 | Value: Undisclosed

MTS served as exclusive financial advisor to Fujifilm on its acquisition of remaining stake of Fujifilm Diosynth Biotechnologies group companies from Mitsubishi Corporation

Seagen Inc.

Announced: 03/13/2023 | Value: $43 billion

MTS served as financial advisor to Seagen on its sale to Pfizer

Concert Pharmaceuticals

Announced: 01/19/2023 | Value: Up to $831 million

MTS served as financial advisor to Concert Pharmaceuticals on its sale to Sun Pharmaceuticals

SavaSeniorCare

Announced: 12/20/2022 | Value: Undisclosed

MTS served as financial advisor to SavaSeniorCare on a restructuring plan whereby it relinquished operating control of all its skilled nursing facilities

Eisai

Announced: 12/19/2022 | Value: $160 million (plus milestone payments and royalties)

MTS served as exclusive financial advisor to Eisai on its divestiture of US rights for FYCOMPA® to Catalyst Pharmaceuticals

SCAN Group

Announced: 12/14/2022 | Value: Undisclosed

MTS serves as exclusive financial advisor to SCAN Group on its combination with CareOregon

BehaVR

Announced: 12/13/2022 | Value: Undisclosed

MTS served as exclusive financial advisor to BehaVR on its merger with OxfordVR

Minoryx Therapeutics

Announced: 11/10/2022 | Value: Up to €258 million

MTS serves as exclusive financial advisor to Minoryx Therapeutics on its exclusive European licensing agreement of Leriglitazone with Neuraxpharm Group

Horizon Blue Cross Blue Shield of New Jersey

Announced: 11/01/2022 | Value: Undisclosed

MTS served as exclusive financial advisor to Horizon Blue Cross Blue Shield of New Jersey in connection with its Mutualization

Aravive, Inc

Announced: 10/25/2022 | Value: $41 million

MTS served as exclusive placement agent to Aravive, Inc. on its PIPE offering

Applied Genetic Technologies Corporation (AGTC)

Announced: 10/23/2022 | Value: $73.5 million

MTS served as exclusive financial advisor to Applied Genetic Technologies Corporation (AGTC) on its sale to Syncona

Zymeworks, Inc.

Announced: 10/19/2022 | Value: $1.8 billion

MTS served as exclusive financial advisor to Zymeworks on its exclusive global licensing agreement of Zanidatamab with Jazz Pharmaceuticals

Horizon Blue Cross Blue Shield of New Jersey

Announced: 10/10/2022 | Value: Undisclosed

MTS served as exclusive financial advisor to Horizon Blue Cross Blue Shield of New Jersey in connection with the Expansion of Braven

Forefront Telecare

Announced: 9/1/2022 | Value: Undisclosed

MTS served as financial advisor to Forefront Telecare on its sale to SOC Telemed, a portfolio company of Patient Square Capital

DeliverLean

Announced: 8/29/2022 | Value: Undisclosed

MTS served as financial advisor to DeliverLean on its sale to NationsBenefits

JCR Pharmaceuticals

Announced: 7/27/2022 | Value: $45 million

MTS served as exclusive financial advisor to JCR Pharmaceuticals on its strategic minority equity investment in Mycenax Biotech

Theravance Biopharma

Announced: 7/13/2022 | Value: $1.5 billion

MTS served as financial advisor to Theravance Biopharma on its 85% economic interest sale of TRELEGY to Royalty Pharma

Epizyme, Inc.

Announced: 6/27/2022 | Value: $418 million

MTS served as financial advisor to Epizyme on its sale to Ipsen

Ring2Media

Announced: 6/16/2022 | Value: Undisclosed

MTS served as exclusive financial advisor to Ring2Media on its sale to Quote.com (a portfolio company of Osceola Capital)

Jvion

Announced: 5/31/2022 | Value: Undisclosed

MTS served as exclusive financial advisor to Jvion on its sale to Lightbeam Health Solutions (a portfolio company of Primus Capital)

SCAN Group

Announced: 5/26/2022 | Value: Undisclosed

MTS served as exclusive financial advisor to SCAN Group on its acquisition of The Residentialist Group

Entasis Therapeutics

Announced: 5/23/2022 | Value: $113 million

MTS served as exclusive financial advisor to Entasis Therapeutics on its sale to Innoviva

Sanderling Renal Services

Announced: 5/16/2022 | Value: Undisclosed

MTS served as exclusive financial advisor to Sanderling Renal Services on its growth equity investment by Pharos Capital

Botanix Pharmaceuticals

Announced: 5/3/2022 | Value: Up to $177 million

MTS served as exclusive financial advisor to Botanix Pharmaceuticals on its in-licensing of Sofpironium Bromide

Vytalize Health

Announced: 4/11/2022 | Value: $53 million

MTS served as the exclusive placement agent for Vytalize Health’s $53mm Series B financing

Lyra Therapeutics

Announced: 4/8/2022 | Value: $100 million

MTS served as exclusive placement agent to Lyra Therapeutics on its PIPE offering

Professional Health Care Network

Announced: 3/30/2022 | Value: Undisclosed

MTS served as exclusive financial advisor to Professional Health Care Network in its majority recapitalization by The Vistria Group

VectivBio

Announced: 3/30/2022 | Value: $25 million upfront, plus development cost sharing, milestones up to $170mm & double digit royalties

MTS served as exclusive financial advisor to VectivBio on its out-licensing of apraglutide in Japan to Asahi Kasei Pharma

Homology Medicines, Inc.

Announced: 1/28/2022 | Value: $130 million

MTS served as financial advisor to Homology Medicines in its partnership with Oxford Biomedica to form Oxford Biomedica Solutions LLC, with Homology as 20% owner

Fujifilm

Announced: 1/26/2022 | Value: $100 million

MTS served as exclusive financial advisor to Fujifilm in its acquisition of Atara Biotherapeutics’ T-cell Operations and Manufacturing (ATOM) facility

ADC Therapeutics SA

Announced: 1/18/2022 | Value: Upfront $30 million, plus milestones up to $205 million and double-digit royalties

MTS served as exclusive financial advisor to ADC Therapeutics on its out-licensing of ZYNLONTA in Japan to Mitsubishi Tanabe Pharma

Fuji Pharma

Announced: 12/28/2021 | Value: Undisclosed

MTS served as exclusive financial advisor to Fuji Pharma on its acquisition of SULPREP, MINCLEA, FOLIAMIN, and OSVAN in Japan from Nihon Pharma

Bellicum Pharmaceuticals

Announced: 12/6/2021 | Value: $35 million

MTS served as exclusive placement agent to Bellicum Pharmaceuticals on its PIPE offering

BehaVR

Announced: 10/18/2021 | Value: Up to $163 million

MTS served as exclusive financial advisor to BehaVR on its collaboration with Sumitomo Dainippon Pharma

One Medical Passport

Announced: 10/5/2021 | Value: Undisclosed

MTS served as exclusive financial advisor to One Medical Passport on its sale to Mnet Health

JCR Pharmaceuticals Co., Ltd.

Announced: 9/30/2021 | Value: Undisclosed

MTS served as exclusive financial advisor to JCR Pharmaceuticals on its collaboration and license agreement to commercialize JR-141 with Takeda Pharmaceutical

Arbor Pharmaceuticals, Inc

Announced: 8/24/2021 | Value: Undisclosed

MTS served as exclusive financial advisor to Arbor Pharmaceuticals on its sale to Azurity Pharmaceuticals

ImmunoTek

Announced: 7/30/2021 | Value: Undisclosed

MTS served as exclusive financial advisor to ImmunoTek on its development and supply agreement with Grifols

MedRhythms

Announced: 7/28/2021 | Value: $25 million

MTS served as exclusive placement agent to MedRhythms on its $25 million Series B financing

Otsuka Pharmaceutical

Announced: 7/23/2021 | Value: $20 million

MTS served as the exclusive financial advisor to Otsuka America Pharmaceutical on the divestiture of its North American BreathTek business to Meridian Bioscience

Seres Therapeutics, Inc.

Announced: 7/1/2021 | Value: $525 million

MTS served as the exclusive financial advisor to Seres Therapeutics on its co-commercialization license agreement with Nestlé Health Science for SER-109

Catalyst Pharmaceuticals, Inc.

Announced: 6/28/2021 | Value: Undisclosed

MTS served as the exclusive financial advisor to Catalyst Pharmaceuticals on its outlicensing of Firdapse in Japan to DyDo Pharma

onehome

Announced: 6/14/2021 | Value: Undisclosed

MTS served as lead financial advisor to onehome on its sale to Humana

Kinderhook Industries, Inc.

Announced: 6/14/2021 | Value: Undisclosed

MTS served as exclusive financial advisor to Kinderhook Industries’ portfolio company on acquisition of Medical Card System

Strongbridge Biopharma

Announced: 5/24/2021 | Value: $267 million

MTS served as exclusive financial advisor to Strongbridge Biopharma on its sale to Xeris Pharmaceuticals

Synzi

Announced: 5/7/2021 | Value: $42.5 million

MTS served as exclusive financial advisor to Synzi on its sale to AMN Healthcare

Genesis Healthcare

Announced: 03/03/2021 | Value: Undisclosed

MTS served as exclusive financial advisor to Genesis Healthcare in connection with its restructuring

Applied Genetic Technologies Corporation (AGTC)

Announced: 1/28/2021 | Value: $75 million

Joint bookrunner and financial advisor on the confidentially marketed public offering (CMPO) for Applied Genetic Technologies Corporation (NASDAQ: AGTC)

Acorda Therapeutics

Announced: 1/13/2021 | Value: $80 million

MTS served as exclusive financial advisor to Acorda on its sale of a spray drying manufacturing facility

Magellan Health, Inc.

Announced: 12/22/2020 | Value: Undisclosed

MTS served as exclusive financial advisor to Magellan on its acquisition of a majority interest in Bayless Integrated Healthcare

Neos Therapeutics, Inc.

Announced: 12/10/2020 | Value: Undisclosed

MTS served as exclusive financial advisor to Neos Therapeutics on its stock-for-stock merger with Aytu Bioscience

Sunesis Pharmaceuticals, Inc.

Announced: 11/30/2020 | Value: Undisclosed

Financial advisor to Sunesis Pharmaceuticals, Inc. on its all-stock merger with Viracta Therapeutics, Inc.

Cystic Fibrosis Foundation

Announced: 11/2/2020 | Value: $575 million upfront plus a $75 million potential milestone payment

MTS served as exclusive financial advisor to the Cystic Fibrosis Foundation in the structured sale of its residual royalty interests in Vertex’s Cystic Fibrosis Assets

Magellan Health, Inc.

Announced: 10/29/2020 | Value: Undisclosed

MTS served as exclusive financial advisor to Magellan on its strategic minority equity investment in Kaden Health

doctor.com

Announced: 10/13/2020 | Value: Undisclosed

MTS served as exclusive financial advisor to doctor.com on its sale to Press Ganey Associates

University of Maryland Medical System

Announced: 10/12/2020 | Value: Undisclosed

Exclusive financial advisor to the University of Maryland Medical System in connection with the sale of its Medicare and Medicaid plans to CareFirst Blue Cross Blue Shield

Galecto Inc.

Announced: 9/25/2020 | Value: $64 million

Placement agent for Galecto Inc. on its $64mm Crossover financing

Strongbridge Biopharma

Announced: 9/16/2020 | Value: $25 million

MTS served as financial advisor to Strongbridge Biopharma on its public offering

MiNA Therapeutics

Announced: 9/10/2020 | Value: £23 million

Exclusive placement agent for MiNA Therapeutics on its £23 million ($30mm) Series A financing

Verastem Oncology

Announced: 8/10/2020 | Value: Up to $311 million plus double-digit royalty on US + EU sales and 50% of net royalties on previously out licensed regions

MTS served as financial advisor to Verastem Oncology in Sale of COPIKTRA to Secura Bio

Lexicon Pharmaceuticals

Announced: 7/30/2020 | Value: Up to $224 million

MTS served as financial advisor to Lexicon Pharmaceuticals in Sale of XERMELO to TerSera Therapeutics

Healthcare Merger Corp

Announced: 7/29/2020 | Value: $720 million

MTS served as financial advisor to Healthcare Merger Corp on its merger with SOC Telemed

Chinook Therapeutics

Announced: 6/2/2020 | Value: Undisclosed

Exclusive financial advisor to Chinook Therapeutics on its all-stock reverse merger with Aduro Biotech

Larimar Therapeutics

Announced: 5/29/2020 | Value: $80 million

MTS Served as exclusive placement agent to Larimar Therapeutics (NASDAQ:LRMR) on its $80mm PIPE financing

Geron Corporation

Announced: 5/21/2020 | Value: $150 million

Joint bookrunner on the confidentially marketed public offering for Geron Corporation (NASDAQ: GERN)

scPharmaceuticals

Announced: 5/20/2020 | Value: $50 million

MTS served as financial advisor in public offering of common stock

Quorum Health Corporation

Announced: 4/7/2020 | Value: $1.3 billion

MTS served as exclusive financial advisor to Quorum in connection with the prepackaged Chapter 11 recapitalization

JCR Pharmaceuticals Co., Ltd

Announced: 3/26/2020 | Value: Undisclosed

MTS served as exclusive financial advisor to JCR Pharmaceuticals (TSE:4552) on its acquisition of ArmaGen

Zyla Life Sciences

Announced: 3/16/2020 | Value: Undisclosed

MTS served as exclusive financial advisor to Zyla Life Sciences on its stock-for-stock merger with Assertio Therapeutics

Pager, Inc.

Announced: 3/9/2020 | Value: $33 million

Exclusive financial advisor to Pager on its $33mm private placement

Lincare

Announced: 3/4/2020 | Value: Undisclosed

MTS served as exclusive financial advisor to Lincare on its sale of Home Infusion assets to KabaFusion

R1 RCM

Announced: 1/13/2020 | Value: $190 million

Served as financial advisor to R1 RCM (NASDAQ: RCM) on its acquisition of SCI Solutions

Universal Care, Inc. (d/b/a/ Brand New Day)

Announced: 1/8/2020 | Value: $280 million

Exclusive financial advisor to Universal Care, Inc. (d/b/a/ Brand New Day) on its sale to Bright Health

Healthgrades

Announced: 1/7/2020 | Value: Undisclosed

MTS served as exclusive financial advisor to Healthgrades on its acquisition of Evariant

Gilead Sciences, Inc.

Announced: 12/24/2019 | Value: Undisclosed

Exclusive financial advisor to Gilead Sciences on its co-promotion of FILGOTINIB with Eisai in Japan

Zafgen, Inc.

Announced: 12/18/2019 | Value: Undisclosed

Exclusive financial advisor to Zafgen, Inc. on its all-stock merger with Chondrial Therapeutics, Inc.

Veloxis Pharmaceuticals A/S

Announced: 11/25/2019 | Value: $1.318 billion

Exclusive financial advisor to Veloxis on its sale to Asahi Kasei Group

Blue Cross and Blue Shield of Arizona, Inc.

Announced: 11/7/2019 | Value: Undisclosed

Exclusive financial advisor to Blue Cross and Blue Shield of Arizona, Inc. on its pending acquisition of Steward Health Choice Arizona from Steward Health Care System

Roivant Sciences

Announced: 10/31/2019 | Value: $3.0 billion

Exclusive financial advisor to Roivant in its sale of select assets, access to Health technology, and 10% equity to Dainippon Sumitomo Pharma

Genesis HealthCare

Announced: 10/16/2019 | Value: $89 million for the sale of 8 facilities and undisclosed value of JV in 18 facilities with undisclosed investor

MTS served as financial advisor to Genesis Healthcare on its sale of 8 facilities and formation of a joint venture in 18 facilities with an undisclosed investor

H. Lundbeck A/S

Announced: 9/16/2019 | Value: $2.0 billion

MTS served as financial advisor to Lundbeck on its acquisition of Alder BioPharmaceuticals

Cavion, Inc.

Announced: 8/12/2019 | Value: Up to $312.5 million

Exclusive financial advisor to Cavion in connection with its sale to Jazz Pharmaceuticals

Neoleukin Therapeutics, Inc.

Announced: 8/6/2019 | Value: Undisclosed

Exclusive financial advisor to Neoleukin Therapeutics on its reverse merger with Aquinox Pharmaceuticals

Vical Incorporated

Announced: 6/3/2019 | Value: Undisclosed

Exclusive Financial Advisor to Vical Incorporated on its all-stock merger with Brickell Biotech, Inc.

Amryt Pharma plc

Announced: 5/21/2019 | Value: $518 million in combined enterprise value, plus up to an additional $85mm in CVRs to Amryt shareholders

Exclusive financial advisor to Amryt Pharma plc on its all-stock merger with Aegerion Pharmaceuticals, Inc.

LifeArc

Announced: 5/20/2019 | Value: $1.297 billion

MTS served as exclusive financial advisor to LifeArc on the structured sale of a portion of its worldwide royalty interests in Keytruda

Realm Therapeutics

Announced: 5/16/2019 | Value:

Financial advisor to Realm Therapeutics on its reverse merger with ESSA Pharma

University of Newcastle upon Tyne

Announced: 4/1/2019 | Value: $31 million

Exclusive financial advisor to Newcastle University in the structured sale of a portion of its royalty interests in RUBRACA

Promise Healthcare

Announced: 2/13/2019 | Value: $84 million

Exclusive financial advisor to Promise Healthcare Group in its Section 363 sale of Silver Lake Medical Center to L.A. Downtown Medical Center

Arsenal Capital Partners

Announced: 1/17/2019 | Value: Undisclosed

MTS served as exclusive financial advisor to Arsenal Capital Partners on its acquisition of Accumen Inc.

Activate Healthcare

Announced: 1/16/2019 | Value: Undisclosed

MTS served as exclusive financial advisor to Activate Healthcare on its acquisition by Paladina Health.

SMV Property Holdings

Announced: 1/11/2019 | Value: $835 million

MTS Health Partners acted as exclusive financial advisor to SMV Property Holdings in connection with a $835mm refinancing

Immunogen, Inc.

Announced: 1/8/2019 | Value: $65 million

Exclusive financial advisor to ImmunoGen on its sale of residual Kadcyla royalties

Shionogi & Co., Ltd.

Announced: 12/19/2018 | Value: Upfront of $5 million and equity investment of $35 million, plus milestones up to $120mm and tiered royalty on sales if successfully commercialized

Exclusive financial advisor to Shionogi on its strategic collaboration with Tetra Discovery Partners to license Tetra’s BPN14770 in Japan, Taiwan and Korea.

Strongbridge Biopharma

Announced: 10/31/2018 | Value: ~$182 million cash and PIPE investment plus additional undisclosed amount for inventory and sales force for three years

Exclusive financial advisor to Strongbridge Biopharma on its sale of US and Canadian rights for Macrilen to Novo Nordisk

Adynxx

Announced: 10/12/2018 | Value: Undisclosed

Exclusive financial advisor to Adynxx on its all-stock merger agreement with Alliqua BioMedical

Otsuka Pharmaceutical

Announced: 10/11/2018 | Value: $80 million

Exclusive Financial Advisor to Otsuka on its expanded collaboration agreement with Proteus to Advance Digital Medicines For Mental Health

Poxel

Announced: 8/30/2018 | Value: Upfront ~$18 million, plus additional undisclosed development and commercial milestones

Exclusive financial advisor to Poxel on its acquisition of DRX-065 and other programs from DeuteRx

Ligand Pharmaceuticals

Announced: 8/9/2018 | Value: £32.8 million

Financial advisor to Ligand Pharmaceuticals in its acquisition of Vernalis

Psyadon Pharmaceuticals

Announced: 8/8/2018 | Value: Undisclosed

Exclusive financial advisor to Psyadon Pharmaceuticals in connection with its sale to Paragon Biosciences

ReViral

Announced: 8/1/2018 | Value: $55 million

Exclusive placement agent for ReViral Ltd on its $55mm Series B financing

Protalix BioTherapeutics

Announced: 7/24/2018 | Value: Up to $805 million

Exclusive financial advisor to Protalix on its sale of the U.S. commercialization and development rights for PRX-102 to Chiesi Farmaceutici

Apollo Global Management / RCCH HealthCare Partners

Announced: 7/23/2018 | Value: $5.6 billion

MTS served as financial advisor to Apollo/RCCH on its $5.6 Billion Cash Merger with LifePoint Health (NASDAQ: LPNT)

Jazz Pharmaceuticals

Announced: 6/29/2018 | Value: $80 million

Exclusive Financial Advisor to Jazz Pharmaceuticals in its sale of Prialt to TerSera Therapeutics.

Dana-Farber Cancer Institute

Announced: 6/29/2018 | Value: Undisclosed

MTS served as exclusive financial advisor to Dana-Farber on the sale of royalty interests

Keryx Biopharmaceuticals

Announced: 6/28/2018 | Value: $1.3 billion

Financial advisor to Keryx Biopharmaceuticals in its all-stock merger with Akebia Therapeutics

University of Massachusetts Medical School

Announced: 6/22/2018 | Value: Undisclosed

Exclusive financial advisor to the University of Massachusetts Medical School in the structured sale of a portion of its US royalty interests in SPINRAZA

Boston Children’s Hospital

Announced: 6/19/2018 | Value: $51.5 million

Exclusive financial advisor to Boston Children’s Hospital in the structured sale of royalty interests in VONVENDI

Shionogi & Co., Ltd.

Announced: 6/13/2018 | Value: Upfront $90 million, plus additional development and commercial milestones of up to $485 million

Exclusive financial advisor to Shionogi on its strategic collaboration with Sage Therapeutics to develop and commercialize SAGE-217 in Japan, Taiwan and South Korea

Cold Spring Harbor Laboratory

Announced: 6/12/2018 | Value: Undisclosed

Exclusive financial advisor to CSHL in the structured sale of a portion of its worldwide royalty interests in SPINRAZA

Cyteir Therapeutics

Announced: 4/30/2018 | Value: $35 million

Sole placement agent

Arbutus Biopharma

Announced: 4/11/2018 | Value: Undisclosed

MTS advised the Special Committee to the Board of Directors of Arbutus on the launch of Genevant Sciences, a jointly-owned company with Roivant Sciences

pSivida

Announced: 3/28/2018 | Value: Up to $125 million

Exclusive financial advisor to pSivida in connection with its acquisition of Icon Bioscience to form EyePoint Pharmaceuticals

Ameritox

Announced: 3/5/2018 | Value: Undisclosed

Exclusive financial advisor to Ameritox in connection with its sale to Aegis Sciences Corporation, a portfolio company of Abry Partners

Addex Therapeutics

Announced: 3/5/2018 | Value: $42.6 million

Sole US placement agent for Addex Therapeutics (SWX: ADXN) in connection with a $42.6 million PIPE financing

Churchill Pharmaceuticals

Announced: 1/25/2018 | Value: Undisclosed Partner

Exclusive financial advisor to Churchill Pharmaceuticals on its outlicensing of YONSA to an Undisclosed Partner

Strongbridge Biopharma

Announced: 1/17/2018 | Value: Up to $203 million

Acquisition of US and Canadian rights to MACRILEN from Aeterna Zentaris

Novozymes

Announced: 12/28/2017 | Value: Undisclosed

Exclusive financial advisor to Novozymes on the divestiture of Albumedix

ImmusanT

Announced: 11/14/2017 | Value: $40 million

Sole placement agent in Series C private financing

Ocera Therapeutics

Announced: 11/2/2017 | Value: Up to $117 million

Clinical-stage biopharmaceutical company focused on the development and commercialization of OCR-002 (ornithine phenylacetate) in both intravenous (IV) and oral formulations

Envisia Therapeutics

Announced: 10/5/2017 | Value: $25 million plus additional undisclosed product approval milestones

Exclusive financial advisor to Envisia Therapeutics on its asset sale to Aerie Pharmaceuticals

Arbutus Biopharma

Announced: 10/2/2017 | Value: $116.4 million

Financial Advisor to Special Committee of the Board of Directors on Private Placement

Dimension Therapeutics

Announced: 10/2/2017 | Value: $171 million

Exclusive financial advisor to Dimension Therapeutics in connection with its sale to Ultragenyx Pharmaceutical

Realm Therapeutics

Announced: 9/21/2017 | Value: $26 million

Realm Therapeutics (AIM:RLM) announced an upsized $26 million private placement

Walter and Eliza Hall Institute

Announced: 7/27/2017 | Value: $325 million

Exclusive financial advisor to WEHI in the structured sale of a portion of its worldwide royalty interests in venetoclax

Physicians Dialysis and GMF Capital

Announced: 5/1/2017 | Value: Undisclosed

Exclusive financial and debt advisor to Physicians Dialysis and GMF Capital in connection with acquisition of assets from DaVita

Zymeworks

Announced: 4/27/2017 | Value: $59 million

Financial advisor to Zymeworks in connection with its IPO

Verona Pharma plc

Announced: 4/26/2017 | Value: $80 million

Financial advisor to Verona Pharma in connection with its U.S. IPO

Caladrius Biosciences

Announced: 3/16/2017 | Value: $75 million upfront, plus $5 million additional potential sales milestone payment

Exclusive financial advisor to Caladrius Biosciences on the sale of its remaining 80.1% equity stake in its PCT, LLC subsidiary

Otsuka Pharmaceutical

Announced: 3/2/2017 | Value: $100 million upfront, plus up to $150mm in development & regulatory milestones, plus additional potential sales milestone payments

Exclusive financial advisor to Otsuka Pharmaceutical Co., Ltd. on its acquisition of Neurovance, Inc.

Arizona Center for Cancer Care

Announced: 1/30/2017 | Value: Undisclosed

Exclusive financial advisor to AZCCC in connection with its Joint Venture with HonorHealth

CoLucid Pharmaceuticals

Announced: 1/18/2017 | Value: $960 million

Exclusive sell-side advisor to CoLucid Pharmaceuticals on its sale to Eli Lilly and Company

Ipsen

Announced: 1/8/2017 | Value: $575 million plus up to $450 million in contingent payments

Exclusive financial advisor to Ipsen on its acquisition of Onivyde from Merrimack Pharmaceuticals

OncoGenex Pharmaceuticals

Announced: 1/5/2017 | Value: Undisclosed

Exclusive financial advisor to OncoGenex Pharmaceuticals on its all-stock merger agreement with Achieve Life Science

Shire plc (NASDAQ:SHPG)

Announced: 1/4/2017 | Value: Undisclosed

Exclusive financial advisor to Shire on the spin-out of its MRT platform to RaNA Therapeutics

Universal American

Announced: 11/17/2016 | Value: $800 million

MTS advised Universal American on its sale to WellCare Health Plans

Ocular Technologies (an Auven Therapeutics portfolio company)

Announced: 10/26/2016 | Value: $40 million plus contingent payments

Exclusive financial advisor to Auven Therapeutics in the sale of Seciera, a Phase 3 clinical asset for the treatment of dry eye disease

Horizon Pharma Plc

Announced: 9/12/2016 | Value: $800 million

Lead financial advisor to Horizon Pharma Plc on its acquisition of Raptor Pharmaceutical

PathGroup

Announced: 8/1/2016 | Value: Undisclosed

Exclusive financial advisor to PathGroup in connection with its sale to Pritzker Group Private Capital

Dana-Farber Cancer Institute

Announced: 7/29/2016 | Value: $168 million

Long-term exclusive financial advisor to DFCI in the structured sale of a portion of its royalty interests in certain PD-L1 products and product candidates

Medical Research Council Technology

Announced: 7/8/2016 | Value: $150 million

Exclusive financial advisor to MRCT in the structured sale of a portion of its worldwide royalty interests in KEYTRUDA

Bloom Health

Announced: 07/06/2016 | Value: Undisclosed

Sole advisor to Bloom Health on its sale to Empyrean Benefit Solutions

Verona Pharma

Announced: 06/17/2016 | Value: $63.3 million

Sole US placement agent for Verona Pharma in connection with raising $63.3 million in a PIPE financing

Celator Pharmaceuticals

Announced: 05/31/2016 | Value: $1.5 billion

Exclusive financial advisor to Celator in connection with its sale to Jazz Pharmaceuticals

Synta Pharmaceuticals

Announced: 04/14/2016 | Value: Undisclosed

Financial Advisor to Synta Pharmaceuticals on its all-stock merger agreement with Madrigal Pharmaceuticals

Madrigal Pharmaceuticals

Announced: 04/14/2016 | Value: Undisclosed

Strategic Advisor to Madrigal Pharmaceuticals on its all-stock merger agreement with Synta Pharmaceuticals

Starmount

Announced: 04/04/2016 | Value: $127 million

Exclusive financial advisor to Starmount in connection with its sale to Unum Group (NYSE: UNM)

Celator Pharmaceuticals

Announced: 03/23/2016 | Value: $44 million

Financial advisor to Celator Pharmaceuticals (NASDAQ:CPXX) on its $43.7 Million Public Offering

Caladrius Biosciences

Announced: 03/14/2016 | Value: $25 million

Exclusive financial advisor to Caladrius Biosciences on its Strategic Global Collaboration and Asia License Agreement with Hitachi Chemical (19.9% Equity Stake for $19.4 Million and $5.6 Million Upfront)

Signature Hospice and Home Health

Announced: 03/09/2016 | Value: $84 million

Exclusive financial advisor to Genesis Healthcare (NYSE: GEN) on the sale of its Signature Hospice and Home Health operations to Hospice Compassus

Laurel Health Care Company

Announced: 02/02/2016 | Value: Undisclosed

Sale of real estate assets to Omega Healthcare Investors as well as the sale of operations to Ciena Healthcare

Tarveda Therapeutics (formerly Blend Therapeutics)

Announced: 01/27/2016 | Value: $38 million

Sole placement agent for Tarveda Therapeutics on its $38 Million Private Placement

Acorda Therapeutics

Announced: 01/19/2016 | Value: $363 million

Financial advisor to Acorda Therapeutics on the acquisition of Biotie Therapies

Aprecia Pharmaceuticals

Announced: 01/14/2016 | Value: $50 million

Sole placement agent for Aprecia Pharmaceuticals on its $50 Million Private Placement

Zymeworks

Announced: 01/08/2016 | Value: $62 million

Lead placement agent for Zymeworks in connection with raising $61.5 million of Series A financing

Diffusion Pharmaceuticals LLC

Announced: 12/15/2015 | Value: Undisclosed

Exclusive financial advisor to Diffusion Pharmaceuticals on its merger with RestorGenex Corporation

Velicept Therapeutics

Announced: 11/24/2015 | Value: $20 million

Sole placement agent for Velicept Therapeutics on its $20 million Private Placement

Examination Management Services Inc.

Announced: 11/03/2015 | Value: Undisclosed

Exclusive financial advisor to EMSI in connection with its sale to Beecken Petty O’Keefe

StrataDx

Announced: 10/01/2015 | Value: Undisclosed

Exclusive financial advisor to StrataDx in connection with its sale to Dermatopathology Experts

Health Diagnostic Laboratory

Announced: 09/11/2015 | Value: $37.1 million

Financial advisor to HDL in its Section 363 sale to True Health Diagnostics

Tripex Pharmaceuticals

Announced: 08/20/2015 | Value: $418.4 million

Exclusive advisor for Tripex in connection with its sale of Quinsair to Raptor Pharmaceuticals

Celsus Therapeutics

Announced: 08/18/2015 | Value: $75 million

Placement agent for Celsus in connection with raising $75 million in a PIPE financing

TeamHealth

Announced: 08/04/2015 | Value: $1.6 billion

Financial advisor to TeamHealth on its acquisition of IPC Healthcare

Celsus Therapeutics

Announced: 07/13/2015 | Value: Undisclosed

Financial advisor to Celsus Therapeutics on its merger with Volution Immuno Pharmaceuticals

ARCA biopharma

Announced: 06/11/2015 | Value: $37 million

Sole placement agent for ARCA biopharma in connection with raising $37 million in a PIPE financing

University of Maryland Medical System

Announced: 05/14/2015 | Value: Not Disclosed

Exclusive advisor for the University of Maryland Medical System in connection with its acquisition of Riverside Health

Baxter International Inc.

Announced: 05/12/2015 | Value: $900 million

Financial advisor to Baxter International Inc. on its acquisition of Oncaspar Portfolio from Sigma-Tau Finanziaria S.p.A

ImmunoGen, Inc.

Announced: 03/30/2015 | Value: $200 million

Exclusive financial advisor to ImmunoGen, Inc. in the structured sale of a portion of its worldwide royalty interests in Kadcyla

Champions Oncology

Announced: 03/12/2015 | Value: $14 million

Sole placement agent for Champions Oncology in connection with raising $14 million in a PIPE financing

TRACON Pharmaceuticals, Inc.

Announced: 01/29/2015 | Value: $41 million

Financial advisor to TRACON Pharmaceuticals, Inc. in connection with its Initial Public Offering

Regado Biosciences

Announced: 01/14/2015 | Value: Not Disclosed

Financial advisor to Regado Biosciences on its merger with Tobira Therapeutics

Otsuka Pharmaceutical

Announced: 12/02/2014 | Value: $3.54 billion

Financial advisor to Otsuka Pharmaceutical Co., Ltd. on its acquisition of Avanir Pharmaceuticals, Inc.

Community Health Systems

Announced: 11/07/2014 | Value: Not Disclosed

Exclusive financial advisor to Community Health Systems on its divestiture of Riverview Regional Medical Center to Prime Healthcare Services

GE Capital, Healthcare Financial Services

Announced: 11/05/2014 | Value: $305 million

Exclusive financial advisor to GE Capital, Healthcare Financial Services in its sale of a Long Term Care Real Estate Portfolio to Aviv REIT

Paul Capital

Announced: 10/17/2014 | Value: Not Disclosed

Exclusive financial advisor to Paul Capital on the secondary sale of royalty streams generated by seven pharmaceuticals

Community Health Systems

Announced: 10/13/2014 | Value: Not Disclosed

Exclusive financial advisor to Community Health Systems on its divestiture of Carolina Pines Regional Medical Center to Capella Healthcare

WellSpring Pharmaceutical

Announced: 10/03/2014 | Value: Not Disclosed

Exclusive financial advisor to WellSpring Pharmaceutical Corporation on the sale of its Prescription Pharmaceutical Business

Acorda Therapeutics

Announced: 09/24/2014 | Value: $525 million

Financial advisor to Acorda Therapeutics on the acquisition of Civitas Therapeutics

TRACON Pharmaceuticals

Announced: 09/22/2014 | Value: $27 million

Lead placement agent for Tracon in connection with raising $27.0 million of Series B financing

Aerie Pharmaceuticals, Inc.

Announced: 09/09/2014 | Value: $125 million

Exclusive financial advisor to Aerie Pharmaceuticals, Inc. (NASDAQ: AERI) to enter into a $125m secured convertible debt facility agreement with Deerfield Capital Management for continued development of product pipeline (Rhopressa™ and Roclatan™), general corporate purposes, and strategic growth opportunities

Skilled Healthcare Group

Announced: 08/18/2014 | Value: NA

Exclusive financial advisor to Skilled Healthcare Group Inc. (NYSE:SKH) on its merger with Genesis HealthCare

AesRx

Announced: 07/09/2014 | Value: Not Disclosed

Exclusive financial advisor to AesRx, LLC on its sale to Baxter International Inc.

Nicox

Announced: 07/02/2014 | Value: Up to $120 million

Exclusive financial advisor to Nicox, SA on its acquisition of Aciex Therapeutics, Inc.

Vistria

Announced: 06/24/2014 | Value: Not Disclosed

Financial advisor to Vistria on its acquisition of Angel MedFlight

Cymetrix

Announced: 05/14/2014 | Value: Up to $100 million

Financial advisor to Cymetrix on its sale to Navigant

Alder Biopharmaceuticals Inc

Announced: 05/08/2014 | Value: $80 million

Financial advisor to Alder Biopharmaceuticals Inc in connection with its Initial Public Offering

Corrona

Announced: 04/17/2014 | Value: Not Disclosed

MTS acted as financial advisor on the growth recapitalization of Corrona

Kaléo

Announced: 04/07/2014 | Value: $150 million

Exclusive financial advisor to kaléo to enter into a $150 million debt facility with PDL BioPharma (NASDAQ: PDLI) to enable kaléo to support commercialization of EVZIO™ (naloxone hydrochloride injection) and development of key pipeline products

Promise Healthcare

Announced: 04/02/2014 | Value: Not Disclosed

Financial advisor to Promise Healthcare, Inc. on its acquisition of six healthcare facilities including four long-term acute care hospitals and two skilled nursing facilities

Oxygen Biotherapeutics

Announced: 03/18/2014 | Value: $59.8 million

MTS served as underwriter for the transaction and led efforts with institutional investors participating in the offering

Promise Healthcare

Announced: 03/17/2014 | Value: Not Disclosed

Financial advisor to Promise Healthcare, Inc. on its restructuring

NuPathe Inc.

Announced: 01/21/2014 | Value: $268 million

Financial advisor to NuPathe Inc. on its sale to Teva Pharmaceutical Industries.

Iroko Pharmaceuticals

Announced: 11/21/2013 | Value: $75 million

Exclusive financial advisor to Iroko to enter into a $75m debt facility agreement to support general business operations and the launch of Zorvolex (diclofenac)

Almost Family, Inc.

Announced: 11/5/2013 | Value: $75.5 million

Financial advisor to Almost Family, Inc. on its acquisition of SunCrest Healthcare

Miraca Life Sciences

Announced: 10/23/2013 | Value: Not Disclosed

Financial advisor to Miraca Life Sciences on its acquisition of PLUS Diagnostics

La Jolla Pharmaceutical

Announced: 09/25/2013 | Value: $10 million

Sole placement agent for La Jolla Pharmaceutical Company in connection with raising $10.0 million through common and preferred shares

Celsus Therapeutics

Announced: 09/19/2013 | Value: $12.5 million

Placement agent for Celsus Therapeutics in connection with raising $12.5 million through common shares

QuantiaMD

Announced: 9/3/2013 | Value: $10 million

Sole placement agent for Quantia Communications, Inc. on its $10 million Private Placement

Acorda Therapeutics

Announced: 7/9/2013 | Value: Not Disclosed

Financial advisor to Acorda Therapeutics on the acquisition of Qutenza™ and NP-1998 from NeurogesX

University of Pennsylvania

Announced: 6/25/2013 | Value: $55 million

Exclusive financial advisor to University of Pennsylvania in the structured sale of a portion of its worldwide royalty interests in Juxtapid

Laboratory Partners

Announced: 6/3/2013 | Value: Not Disclosed

Financial advisor to Laboratory Partners on the sale of its physician outreach business

AmeriHealth Caritas

Announced: 5/1/2013 | Value: Not Disclosed

Financial advisor to AmeriHealth Caritas on its acquisition of DC Chartered Health Plan assets

RXi Pharmaceuticals Corporation

Announced: 3/1/2013 | Value: $16.4 million

Sole placement agent for RXI Pharmaceuticals Corp. in connection with raising $16.4 million through the sale of common shares

Progenics Pharmaceuticals

Announced: 1/22/2013 | Value: Up to $105 million

Financial advisor to Progenics Pharmaceuticals, Inc on its acquisition of Molecular Insight Pharmaceuticals

TractManager Inc.

Announced: 1/7/2013 | Value: Not Disclosed

Exclusive financial advisor to TractManager, Inc. in connection with the majority recapitization investment by Arsenal Capital Partners

Florida Clinical Laboratory

Announced: 12/31/2012 | Value: Not Disclosed

Exclusive financial advisor to Florida Clinical Laboratory on its sale to Bio-Reference Laboratories, Inc.

BioScrip

Announced: 12/13/2012 | Value: $70 million

Financial advisor to BioScrip Inc. on its acquisition of HomeChoice Partners, Inc. from DaVita HealthCare Partners

GE Capital, Healthcare Financial Services

Announced: 12/1/2012 | Value: Not Disclosed

Exclusive financial advisor to GE Healthcare Financial Services in its sale of a Long Term Care Real Estate Portfolio to Formation Capital

MethylGene

Announced: 11/21/2012 | Value: $26 million

Acted as a placement agent for MethylGene in connection with raising $26MM in a PIPE financing

NuPathe

Announced: 10/23/2012 | Value: $28 million

Co-placement agent for NuPathe, Inc. in connection with raising $28 million in a PIPE financing

Fibrocell Science

Announced: 10/8/2012 | Value: $45 million

Lead placement agent for Fibrocell Science, Inc. in connection with raising $45 million in a PIPE financing. Strategic Advisor to Fibrocell Science, Inc on its strategic collaboration with Intrexon

Jazz Pharmaceuticals

Announced: 9/6/2012 | Value: $95 Million

Exclusive financial advisor to Jazz Pharmaceuticals on the sale of its Women’s Health Business to Meda AB

Idenix Pharmaceuticals

Announced: 8/2/2012 | Value: $176 million

Financial advisor to Idenix Pharmaceuticals, Inc. on its $176 million follow-on public offering of common stock

BioScrip

Announced: 7/31/2012 | Value: $41 million

Financial advisor to BioScrip Inc. on its acquisition of InfuScience from Cressey & Company

Not Disclosed

Announced: 6/30/2012 | Value: Not Disclosed

Financial advisor to Undisclosed Public Buyer on its acquisition of Healthy Circles

Sun Healthcare

Announced: 6/20/2012 | Value: $275 million

Exclusive financial advisor to Sun Healthcare on its sale to Genesis Healthcare

Lumeris Corporation

Announced: 2/14/2012 | Value: Not Disclosed

Financial advisor to Lumeris Corp. on its acqusition of NaviNet in partnership with Highmark, Horizon Blue Cross Blue Shield of New Jersey and Independence Blue Cross

BioScrip

Announced: 2/2/2012 | Value: $285 million

Financial advisor to BioScrip Inc. on its sale of its community specialty pharmacies and centralized specialty and mail service pharmacy businesses to Walgreens

Idenix Pharmaceuticals

Announced: 11/16/2011 | Value: $61.1 million

Financial advisor to Idenix Pharmaceuticals, Inc. on its $61 million follow-on public offering of common stock

A.P. Pharma

Announced: 6/29/2011 | Value: $24 million

Sole placement agent for AP Pharma in connection with raising $24 million in a PIPE financing

Highmark

Announced: 6/28/2011 | Value: $1.3 billion

Financial advisor to Highmark Inc. in connection with its acquisition of West Penn Allegheny Health System

Trimeris

Announced: 6/13/2011 | Value: $285 million

Exclusive financial advisor to Trimeris Inc. on its reverse merger with Synageva BioPharma Corp

Advanced Vision Research

Announced: 5/3/2011 | Value: $26 million

Exclusive financial advisor to Advanced Vision Research on its sale to Akorn, Inc.

MethylGene

Announced: 3/24/2011 | Value: $35 million

Sole placement agent for MethylGene in connection with raising $35 million in a PIPE financing

Intercell AG

Announced: 2/23/2011 | Value: $45.5 million

Financial advisor to Intercell AG related to the issuance of senior unsecured convertible notes

Sol Amor Hospice

Announced: 1/3/2011 | Value: Not Disclosed

Exclusive financial advisor to Sun Healthcare and its subsidiary SolAmor Hospice on its acquisition of Countryside Hospice

Acadia Pharmaceuticals

Announced: 1/1/2011 | Value: $15 million

Co-placement agent for Acadia Pharmaceuticals Inc. in connection with raising $15 million in a PIPE financing

Aastrom Biosciences

Announced: 12/10/2010 | Value: $22.5 million

Financial advisor to Aastrom Biosciences for its $22.5 million follow-on offering

Neurologix

Announced: 12/6/2010 | Value: $7 million

Lead placement agent for Neurologix, Inc. in connection with raising $7 million in convertible debt

Reata Pharmaceuticals

Announced: 9/23/2010 | Value: $450 million

Strategic advisor to Reata Pharmaceuticals in its landmark ex-US partnership with Abbott Labs

Sun Healthcare

Announced: 8/13/2010 | Value: $238 million

Financial advisor to Sun Healthcare on its equity offering in connection with its restructuring and spinof of its real estate assets

Solstice Neurosciences

Announced: 8/13/2010 | Value: Not Disclosed

Exclusive financial advisor to Solstice Neurosciences, LLC on its sale to US WorldMeds

Trubion Pharmaceuticals

Announced: 8/12/2010 | Value: Up to $140 million

Financial advisor to Trubion Pharmaceuticals on its sale to Emergent Biosolutions

NuPathe

Announced: 8/6/2010 | Value: $50 million

Financial advisor to NuPathe, Inc in connection with its Initial Public Offering

Westcliff Medical Laboratories

Announced: 7/18/2010 | Value: $74 million

Exclusive financial advisor to Westcliff Medical Laboratories on its restructuring and sale to Laboratory Corporation of America

Accolade

Announced: 7/1/2010 | Value: $17 million

Sole placement agent for Accolade LLC on its $17 million Private Placement

Sun Healthcare

Announced: 5/24/2010 | Value: $1.6 billion

Financial advisor to Sun Healthcare on its spin of real estate assets into separately traded Sabra Health Care REIT (SBRA)

Inhibitex

Announced: 10/26/2009 | Value: $23 million

Exclusive placement agent for Inhibitex, Inc. in connection with raising $23 million in a PIPE financing

Threshold Pharmaceuticals

Announced: 10/6/2009 | Value: $35 million

Co-placement agent for Threshold Pharmaceuticals Inc. in connection with raising $35 million in a PIPE financing

Neurogen Corporation

Announced: 8/24/2009 | Value: $11 - 27 million

Exclusive financial advisor to Neurogen Corporation on its Sale to Ligand Pharmaceuticals Incorporated

Reata Pharmaceuticals

Announced: 3/27/2009 | Value: $32 million

Sole placement agent for Reata Pharmaceuticals, Inc on its $32 million Private Placement

Undisclosed Not-for-Profit Managed Care Organization

Announced: 2009 | Value: $37 million

Divestiture of dental insurance business of a not-for-profit insurer

GTC Biotherapeutics

Announced: 11/3/2008 | Value: $15 million

Financial advisor to GTC Biotherapeutics, Inc on its $15 million Convertible Debt financing

Oscient Pharmaceuticals

Announced: 10/21/2008 | Value: $213 million

Dealer manager in connection with debt restructuring and recapitalization

Link Medicine

Announced: 9/30/2008 | Value: $40 million

Sole placement agent for Link Medicine Corporation on its $40 million Private Placement

Threshold Pharmaceuticals

Announced: 7/10/2008 | Value: $18 million

Co-placement agent for Threshold Pharmaceuticals Inc. in connection with raising $18 million in a PIPE financing

My Innerview

Announced: 2008 | Value: Not Disclosed

Exclusive financial advisor in connection with its sale to National Research Corporation (NRCI)

Coram

Announced: 10/12/2007 | Value: $350 million

Exclusive financial advisor in connection with its sale to Apria (AHG)

Universal American (UAM)

Announced: 2007 | Value: $630 million

Financial advisor to priviate equity consortium in connection with its investment to fund the acquisition of MemberHealth

Undisclosed Not-for-Profit Managed Care Organization

Announced: 2007 | Value: $125 million

Acquisition of CompWest

Coram

Announced: 2007 | Value: Not Disclosed

Sale of Canadian infusion portfolio

Sun Healthcare Group

Announced: 12/1/2006 | Value: $19 million

Exclusive financial advisor to Sun Healthcare on its sale of SunPlus Home Health Services to AccentCare Home Health

Sun Healthcare Group

Announced: 10/19/2006 | Value: $625 million

Exclusive financial advisor to Sun Healthcare on its acquisition of Harborside Healthcare

Undisclosed Not-for-Profit Managed Care Organization

Announced: 2006 | Value: $240 million

Acquisition of M-Care

Coram

Announced: 2006 | Value: Not Disclosed

Sale of home infusion portfolio

Pacificare (PHSY)

Announced: 2005 | Value: $9 billion

Sale to UnitedHealthcare (UHG)

Undisclosed Not-for-Profit Managed Care Organization

Announced: 2005 | Value: Not Disclosed

Sale of PPO Business

Sun Healthcare Group

Announced: 5/19/2005 | Value: $246 million

Financial advisor to Sun Healthcare on its acquisition of Peak Medical

Pacificare (PHSY)

Announced: 2005 | Value: Not Disclosed

Acquisition of Pacific Life’s group health insurance business

PresGar Companies

Announced: 2004 | Value: $135 million

Restructuring

PresGar Companies

Announced: 2004 | Value: Not Disclosed

Sale of imaging center portfolio to undislosed buyer

Pacificare (PHSY)

Announced: 2004 | Value: $532 million

Acquisition of American Medical Security Group (AMZ)

Sloans Lake

Announced: 2004 | Value: $45 million

Sale to undiclosed financial buyer

Sun Healthcare Group

Announced: 2/1/2004 | Value: $1.4 billion

Exclusive financial advisor to Sun Healthcare Group on its restructuring

Undisclosed Not-for-Profit Managed Care Organization

Announced: 2004 | Value: $200 million

Structured Financing

Undisclosed Not-for-Profit Managed Care Organization

Announced: 2003 | Value: $150 million

Divestiture

Sun Healthcare Group

Announced: 9/1/2003 | Value: $75 million

Financial advisor to Sun Healthcare on its Senior Debt Financing

Sun Healthcare Group

Announced: 6/17/2003 | Value: $90 million

Exclusive financial advisor to Sun Healthcare on its sale of SunScript Pharmacy Services to Omnicare

Pacificare (PHSY)

Announced: 2002 | Value: $200 million

Advisor to PacifiCare in connection with its High-Yield Financing

The Mentor Network

Announced: 2001 | Value: $126 million

Sale to Madison Dearborn Capital Partners

Magellan Health Services (MGLN)

Announced: 2001 | Value: $250 million

Debt Financing

Schein Pharmaceuticals (SHP)

Announced: 2000 | Value: $1.4 billion

Sale to Watson Pharmaceuticals (WPI)